AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

Browse trials for

• Conjunctivitis 361
• Conjunctivitis, Allergic 226

Keywords

• Conjunctivitis
• conjunctival inflammation
• ocular allergies

Conjunctivitis

361 studies on the registry are indexed under Conjunctivitis; 17 are open to participants now.

This study's enrollment of 312 is above the median of 100 across 299 interventional studies indexed under Conjunctivitis.

Lead sponsor

Alcon Research is the lead sponsor of 608 studies on the registry; 9 are open to participants now.

Of its 109 completed or terminated interventional studies of FDA-regulated products, 99 (91%) have results posted.

Study arms

• Experimental
  AL-38583 0.01%

  AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks

  Drug: AL-38583 ophthalmic solution

• Experimental
  AL-38583 0.05%

  AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks

  Drug: AL-38583 ophthalmic solution

• Experimental
  AL-38583 0.2%

  AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks

  Drug: AL-38583 ophthalmic solution

• Placebo comparator
  AL-38583 Vehicle

  AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks

  Drug: AL-38583 ophthalmic solution vehicle

• Active comparator
  MAXIDEX

  Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks

  Drug: Dexamethasone ophthalmic suspension, 0.1%

Interventions

• DrugAL-38583 ophthalmic solution
• DrugAL-38583 ophthalmic solution vehicle

  Inactive ingredients used as a placebo comparator

• DrugDexamethasone ophthalmic suspension, 0.1%

  Also known as: MAXIDEX

Primary outcomes

1. Mean area under the curve 0-7 hours post-CAC for conjunctival redness scores

   Time frame: Day 14

Secondary outcomes

1. Mean daily diary ocular redness scores

   Time frame: 2 week period between Day 0 and Day 14